Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Alectinib in ALK- or RET-Positive Cancer
NCT03194893Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 3, open-label trial of alectinib in ALK-positive non-small cell lung cancer and RET-altered cancer (RET) (2 arms), sponsored by Roche. Primary endpoint: Number of Participants With Adverse Events, Serious Adverse Events and Adverse Events of Special Interest at 8.19 years. Started Jul 2017; status: completed.
02
Drugs
alectinib
03
Conditions
ALK-positive non-small cell lung cancerRET-altered cancer (RET)
Beyond the preview
Go deeper on NCT03194893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194893.